Indivior Pharmaceuticals, Inc. INDV Tax receivable within other current assets

Tax receivable within other current assets at other companies

Sempra EnergySRE

$177M+168%

Energy TransferET

$38M-58.2%

American Electric PowerAEP

$214M—

CBRE GroupCBRE

$192M+86.4%

Dominion EnergyD

$434M—

Keysight TechnologiesKEYS

$111M0.0%

Other financials

Income statement

See full

Revenue$317.0M+19.2%

Gross profit$277.0M+24.8%

Operating income$137.0M+108%

Net income$89.0M+89.4%

EPS (diluted)$0.69+81.6%

Balance sheet

See full

Cash & equivalents$175.0M-53.0%

Total debt$509.0M+37.6%

Total equity-$144.0M+49.5%

Total assets$1.2B-12.9%

Cash flow

See full

Operating cash flow-$9.0M-112%

CapEx$20.0M+300%

Free cash flow-$29.0M-141%

Valuation

See full

Market cap$4.53B+213%

Profitability

See full

Gross margin81.3%+1.5pp

Operating margin25.8%+23.3pp

Net margin19.4%+18.9pp

FCF margin-14.9%—

Returns & leverage

See full

Current ratio0.9×0.0×

Where this comes from

Reported directly by Indivior Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncomeTaxesReceivable.

The official record: Indivior Pharmaceuticals, Inc. ’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Indivior Pharmaceuticals, Inc. 's tax receivable within other current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Indivior Pharmaceuticals, Inc. 's tax receivable within other current assets?: Indivior Pharmaceuticals, Inc. (INDV) reported tax receivable within other current assets of $12M in Q1 2026.
How has Indivior Pharmaceuticals, Inc. 's tax receivable within other current assets changed year-over-year?: Indivior Pharmaceuticals, Inc. 's tax receivable within other current assets decreased by 58.6% year-over-year, from $29M to $12M.